Monophasic Action Potential (MAP) Catheter for Ventricular Tachycardia (VT)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Emory University Hospital, Atlanta, GA
Ventricular Tachycardia (VT)+2 More
Monophasic Action Potential (MAP) Catheter - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to understand why certain hearts have ventricular arrhythmias and help identify areas of the heart that cause arrhythmias. There is still a significant gap in understanding why ventricular arrhythmias occur. This study will examine the electrical properties of the heart tissue to understand how these arrhythmias occur, and hopefully identify areas that might lead to ventricular arrhythmias. The hope is that studying this might be able to improve outcomes during ventricular tachycardia (VT) ablations.

Eligible Conditions

  • Ventricular Tachycardia (VT)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Ventricular Tachycardia (VT)

Study Objectives

2 Primary · 2 Secondary · Reporting Duration: During ablation on Day 1

Day 1
Conduction Velocity
Identify mechanisms of slowed conduction at ILAM
Identify surrogate markers
Waveform Morphology

Trial Safety

Safety Progress

1 of 3

Other trials for Ventricular Tachycardia (VT)

Trial Design

1 Treatment Group

Monophasic Action Potential (MAP) Catheter
1 of 1
Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: Monophasic Action Potential (MAP) Catheter · No Placebo Group · N/A

Monophasic Action Potential (MAP) Catheter
Device
Experimental Group · 1 Intervention: Monophasic Action Potential (MAP) Catheter · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: during ablation on day 1

Trial Background

Prof. Neal Bhatia, Assistant Professor
Principal Investigator
Emory University
Closest Location: Emory University Hospital · Atlanta, GA
Photo of Atlanta  1Photo of Atlanta  2Photo of Atlanta  3
2005First Recorded Clinical Trial
4 TrialsResearching Ventricular Tachycardia (VT)
320 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a single or dual chamber ICD.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.